%20--%3e%3cdefs%3e%3cstyle%3e%20.st0%20{%20fill:%20%23fff;%20}%20%3c/style%3e%3c/defs%3e%3cpath%20class='st0'%20d='M26.036.129C10.532.129,0,11.725,0,26.029s10.883,25.899,26.036,25.899c11.829,0,20.428-6.6,23.938-15.983l-13.165-.147c-2.436,3.026-6.115,4.93-10.677,4.93-6.945,0-12.242-4.724-13.741-11.122l39.12-.039c.138-1.157.209-2.338.209-3.538C51.72,11.725,41.1.129,26.036.129ZM13.144,19.67c2.092-5.128,6.816-8.69,12.987-8.69,6.003,0,10.709,3.571,12.799,8.708l-25.786-.018ZM117.213,18.171c0-1.845,1.504-3.341,3.359-3.341l17.801.005V.129h-19.144c-10.017,0-18.137,8.078-18.137,18.042v18.381l-22.335-.006c-6.028,0-10.915-4.862-10.915-10.858s4.887-10.858,10.915-10.858h20.992V.129h-20.992c-14.376,0-26.029,11.593-26.029,25.893s11.654,25.893,26.029,25.893h22.335v38.088h16.121v-38.088h35.602v-15.363h-35.602v-18.381ZM148.784,40.478v7.434h-35.266v38.417h-8.397v-38.417s-14.216-.005-26.365-.005-21.999-9.798-21.999-21.884,9.849-21.884,21.999-21.884h16.961v6.682h-16.987c-8.24,0-14.92,6.645-14.92,14.842s6.68,14.842,14.92,14.842l26.392-.026v-22.307c0-7.75,6.316-14.032,14.106-14.032h15.45v6.688l-14.106-.005c-4.081,0-7.389,3.291-7.389,7.35v22.307h35.602ZM179.685,20.691c-5.483-1.881-10.305-3.198-10.305-6.019v-.188c0-1.975,1.796-3.48,5.294-3.48,3.687,0,8.698,1.787,13.709,4.703l5.483-9.875C188.383,2.163,181.387,0,174.958,0,164.747,0,156.427,5.737,156.427,15.988v.188c0,9.781,8.036,13.073,15.127,15.142,5.578,1.693,10.494,2.728,10.494,5.831v.188c0,2.257-1.891,3.762-6.051,3.762-4.727,0-10.494-2.069-15.978-6.019l-6.145,9.405c6.713,5.267,14.654,7.618,21.745,7.618,10.967,0,19.381-5.079,19.381-16.27v-.188c0-9.217-8.225-12.602-15.316-14.954Z'/%3e%3c/svg%3e)
Montelukast
M
MEDICATION TYPE
Leukotriene receptor antagonist
INDICATIONS
Prophylaxis of exercise induced asthma, adjunct therapy in the treatment of asthma. Possible effect in CF.
NOTES
Take in the evening.
MEDICAL WARNING
Montelukast should only be administered under the supervision of a healthcare professional. Always verify against current BNF and your local CF protocol before prescribing.